This trial is unknown status.

Condition amphetamine-related disorders
Treatment lobeline
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date September 2004
End date April 2005
Trial size 8 participants
Trial identifier NCT00100074, NIDA-CPU-0007-1


To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Primary purpose diagnostic

Primary Outcomes

time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: - Healthy individuals with a body mass index between 18 and 30. - Willing and able to give written consent. - Must have a negative drug test - Females must have a negative pregnancy test prior to study drug administration - Must have no medical contraindications as determined by routine testing Exclusion Criteria: - Please contact the site for more information

Additional Information

Official title Safety and Tolerability Study of Sublingual Lobeline
Principal investigator Reese Jones, M.D.
Description The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).